EMA validates Ultragenyx’s marketing authorisation application for MPS IIIA gene therapy
Ultragenyx Pharmaceutical announced that the European Medicines Agency has validated its Marketing Authorisation Application for the investigational gene therapy rebisufligene etisparvovec, intended to treat mucopolysaccharidosis type IIIA (Sanfilippo syndrome Type A). The validation means the EMA will begin its formal scientific review, though it does not constitute approval. The therapy already holds PRIME and Orphan Drug designations in Europe and received FDA approval on September 17, 2026. Ultragenyx is also engaging regulators in the UK and Saudi Arabia for future expansion.
Why it matters
The validation initiates the EMA’s review process, a key step toward potential European market access, which could broaden the company’s revenue base. The company’s press release noted that the stock was up 0.59% in pre‑market trading following the announcement, indicating investor optimism.
Key facts
- 1The EMA validated Ultragenyx’s Marketing Authorisation Application for rebisufligene etisparvovec. globenewswire.com
- 2The EMA validation allows the agency to begin its formal scientific review. rttnews.com
- 3Rebisufligene etisparvovec is a single‑dose intravenous AAV9 gene therapy for MPS IIIA. rttnews.com
- 4The therapy has received PRIME and Orphan Drug designations from the EMA. globenewswire.com
- 5Ultragenyx received FDA approval for rebisufligene etisparvovec on September 17, 2026. globenewswire.com
- 6RARE closed at $14.75 on the day of the announcement. rttnews.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.